X线修复交叉互补基因1多态性与进展期胃癌奥沙利铂联合卡培他滨方案化疗疗效的关系  

Relationship between genetic polymorphism of X-ray repair cross-complementing group 1(XRCC1) and clinical outcomes of advanced gastric cancer receiving oxaliplatin plus capecitabine chemotherapy

作　　者：韩磊[1] 董宁宁[2] HAN Lei;DONG Ningning(Department of Oncology,Affiliated Hospital of Jining Medical University,Shandong Jining 272000,China;Department of Gastroenterology,Beijing Friendship Hospital,Capital Medical University/National Clinical Research Center of Gastrointestinal Disease/State Key Laboratory for Digestive Diseases/Beijing Digestive Disease Center/Beijing Key Laboratory for Precancerous Lesion of Digestive Diseases,Beijing 100050,China.)

机构地区：[1]济宁医学院附属医院肿瘤科,山东济宁272000 [2]首都医科大学附属北京友谊医院消化分中心/国家消化系统疾病临床医学研究中心/消化健康全国重点实验室/北京市消化疾病中心/消化疾病癌前病变北京市重点实验室,北京100050

出　　处：《现代肿瘤医学》2024年第14期2570-2573,共4页Journal of Modern Oncology

基　　金：北京市优秀人才培养资助计划(编号:2015000021469G232)。

摘　　要：目的:探讨X线修复交叉互补基因1(X-ray repair cross-complementing group 1,XRCC1) rs25487基因多态性与进展期胃癌奥沙利铂联合卡培他滨(XELOX方案)化疗的疗效及疾病进展时间的关系。方法:本研究为回顾性研究,入组110例进展期胃癌患者,均接受XELOX方案化疗,通过基质辅助激光解吸电离飞行时间质谱法的方法检测XRCC1 rs25487基因分型,分析患者临床病理特点及XRCC1 rs25487基因分型与患者化疗客观有效率(objective response rate, ORR)及疾病进展时间(progression-free survival, PFS)的关系。结果:110例进展期胃癌患者中,携带XRCC1 rs25487GG基因型、AG基因型、AA基因型分别为49例(44.5%)、52例(47.3%)、9例(8.2%),GG基因型患者ORR高于AG/AA基因型患者(53.1%vs 37.7%),但差异未达到统计学意义(χ^(2)=2.594,P=0.107)。GG基因型患者比AG/AA基因型患者PFS更长[6.3个月(95%CI:5.7~6.9)vs 5.0个月(95%CI:4.4~5.6),P=0.049]。患者临床病理特征均与化疗疗效无关,但肿瘤分化程度及TNM分期与PFS有关(P均<0.05)。Cox回归显示,肿瘤分化程度、TNM分期及XRCC1 rs25487是影响PFS的独立因素。结论:XRCC1 rs25487基因型与进展期胃癌患者XELOX方案化疗疗效密切相关,测定XRCC1 rs25487基因型可以为进展期胃癌的个体化治疗提供参考。Objective:To discuss the relationship between X-ray repair cross-complementing group 1(XRCC1)gene polymorphism and clinical outcomes,time to progression of advanced gastric cancer receiving oxaliplatin plus capecitabine chemotherapy(XELOX regimen).Methods:A total of 110 patients with advanced gastric cancer were retrospectively enrolled.All patients received oxaliplatin plus capecitabine chemotherapy.XRCC1 genotype was obtained by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.The relationship between the clinicopathological features of patients and genetic typing of XRCC1 rs25487 and objective response rate(ORR)and progression-free survival(PFS)was analyzed.Results:Among these enrolled patients,49 cases(44.5%)carried XRCC1 rs25487 GG genotype,52 patients(47.3%)AG genotype,and 9 patients(8.2%)AA genotype.GG genotype carriers had a higher ORR than AG/AA genotype carriers(53.1%vs 37.7%,P=0.107).Compared with AG/AA genotype carriers,GG genotype carriers showed statistically longer PFS[6.3 months(95%CI:5.7~6.9)vs 5.0 months(95%CI:4.4~5.6),P=0.049].None of the clinicopathological characteristics was associated with ORR,whereas,tumor differentiation and TNM stage were related to PFS ( P <0.05).Multivariate analysis showed that tumor differentiation,TNM stage and XRCC1 rs25487 genotype were independent prognostic factors of PFS. Conclusion: XRCC1 rs25487 genotype is closely related to treatment outcomes of oxaliplatin plus capecitabine chemotherapy in patients with advanced gastric cancer.Testing for XRCC1 rs25487 genotype may allow identification of patients who will benefit from chemotherapy.

关 键 词：胃肿瘤 X线交错互补修复基因 基因多态性 化学治疗 

分 类 号：R735.2[医药卫生—肿瘤]